TEL AVIV, Israel, September 7, 2017 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ: BLRX)(TASE:
BLRX), a clinical-stage biopharmaceutical company focused on
oncology and immunology, today announced that its Chief Executive
Officer, Philip Serlin, and its
Chief Business Officer, David Malek,
will present a company update at the 19th Annual Rodman &
Renshaw Global Investment Conference at the Lotte New York Palace
Hotel in New York City.
The BioLineRx presentation is scheduled to start at 12:30 p.m. EDT on Tuesday,
September 12, 2017. A live audio webcast of the presentation
will be available online on the Investor Page of the Company's
website. An archive of the event will also be available for those
unable to listen live.
In addition, any investors attending the conference that wish to
meet with Company management for a one-on-one meeting should
contact Lily Khaykina at
lk@rodmanevents.com.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused on
oncology and immunology. The Company in-licenses novel compounds,
develops them through pre-clinical and/or clinical stages, and then
partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML, is in the midst of a Phase 2b
study as an AML consolidation treatment and is expected to initiate
a Phase 3 study in stem cell mobilization for autologous
transplantation; and AGI-134, an immunotherapy treatment in
development for multiple solid tumors, which is expected to
initiate a first-in-man study in the first half of 2018. In
addition, BioLineRx has a strategic collaboration with Novartis for
the co-development of selected Israeli-sourced novel drug
candidates; a collaboration agreement with MSD (known as Merck in
the US and Canada), on the basis
of which the Company has initiated a Phase 2a study in pancreatic
cancer using the combination of BL-8040 and Merck's
KEYTRUDA®; and a collaboration agreement with Genentech,
a member of the Roche Group, to investigate the combination of
BL-8040 and Genentech's Atezolizumab in several Phase 1b/2 studies
for multiple solid tumor indications and AML.
For additional information on BioLineRx, please visit the
Company's website at http://www.biolinerx.com, where you can review
the Company's SEC filings, press releases, announcements and
events. BioLineRx industry updates are also regularly updated on
Facebook, Twitter, and LinkedIn.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-212-554-5482
vivian@pcgadvisory.com
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com
SOURCE BioLineRx Ltd